{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T02:21:09Z","timestamp":1791426069260,"version":"4.3.3"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Ivacaftor is a modern drug used in the treatment of cystic fibrosis. It is highly lipophilic and exhibits a strong positive food effect. These characteristics can be potentially connected to a pronounced lymphatic transport after oral administration.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> A series of studies was conducted to describe the basic pharmacokinetic parameters of ivacaftor in jugular vein cannulated rats when dosed in two distinct formulations: an aqueous suspension and an oil solution. Additionally, an anesthetized mesenteric lymph duct cannulated rat model was studied to precisely assess the extent of lymphatic transport.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Mean \u00b1 SD ivacaftor oral bioavailability was 18.4 \u00b1 3.2% and 16.2 \u00b1 7.8%, respectively, when administered as an aqueous suspension and an oil solution. The relative contribution of the lymphatic transport to the overall bioavailability was 5.91 \u00b1 1.61% and 4.35 \u00b1 1.84%, respectively.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Lymphatic transport plays only a minor role in the process of ivacaftor intestinal absorption, and other factors are, therefore, responsible for its pronounced positive food effect.<\/jats:p>","DOI":"10.3389\/fphar.2024.1331637","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T05:43:55Z","timestamp":1708407835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in rats"],"prefix":"10.3389","volume":"15","author":[{"given":"Ji\u0159\u00ed","family":"Pozniak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Ry\u0161\u00e1nek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Smr\u010dka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Kozl\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"K\u0159\u00ed\u017eek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslava","family":"\u0160mardov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ane\u017eka","family":"Nov\u00e1kov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debanjan","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bobek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahak","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Dou\u0161ov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"\u0160\u00edma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ond\u0159ej","family":"Slana\u0159","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejpb.2020.04.005","article-title":"Preclinical evaluation of new formulation concepts for abiraterone acetate bioavailability enhancement based on the inhibition of pH-induced precipitation","volume":"151","author":"Boleslavska","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/1520-6017(200008)89:8<1073::aid-jps12>3.0.co;2-v","article-title":"Effect of short-medium-and long-chain fatty acid-based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymph-cannulated and non-cannulated rats","volume":"89","author":"Caliph","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0378-5173(86)90027-x","article-title":"Estimating the maximal potential for intestinal lymphatic transport of lipophilic drug molecules","volume":"34","author":"Charman","year":"1986","journal-title":"Int. J. Pharm."},{"key":"B4","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1124\/dmd.113.055053","article-title":"The role of lymphatic transport on the systemic bioavailability of the bcl-2 protein family inhibitors navitoclax (ABT-263) and ABT-199","volume":"42","author":"Choo","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"B5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ejps.2007.09.005","article-title":"The effect of general anesthesia on the intestinal lymphatic transport of lipophilic drugs: comparison between anesthetized and freely moving conscious rat models","volume":"32","author":"Dahan","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s40265-013-0115-2","article-title":"Ivacaftor: a review of its use in patients with cystic fibrosis","volume":"73","author":"Deeks","year":"2013","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s40265-016-0611-2","article-title":"Lumacaftor\/ivacaftor: a review in cystic fibrosis","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"B8","volume-title":"Kalydeco - summary of product characteristics","year":"2012"},{"key":"B9","volume-title":"ICH guideline M10 on bioanalytical method validation and study sample analysis","author":"EMA","year":"2022"},{"key":"B10","volume-title":"Addendum #2 - Pharmacology and toxicology secondary review for NDA 203188","year":"2012"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1007\/s11095-006-9109-z","article-title":"Bioavailability of seocalcitol IV: evaluation of lymphatic transport in conscious rats","volume":"23","author":"Grove","year":"2006","journal-title":"Pharm. Res-Dordr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1021\/js970300n","article-title":"Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor","volume":"87","author":"Hauss","year":"1998","journal-title":"J. Pharm. Sci."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s40265-019-01233-7","article-title":"Elexacaftor\/ivacaftor\/tezacaftor: first approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"121854","DOI":"10.1016\/j.ijpharm.2022.121854","article-title":"Explaining dissolution properties of rivaroxaban cocrystals","volume":"622","author":"Hrinova","year":"2022","journal-title":"Int. J. Pharm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1089\/can.2022.0176","article-title":"Application of oil-in-water cannabidiol emulsion for the treatment of rheumatoid arthritis","volume":"2022","author":"Jelinek","year":"2022","journal-title":"Cannabis Cannabinoid"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1023\/a:1025718513246","article-title":"Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs","volume":"20","author":"Khoo","year":"2003","journal-title":"Pharm. Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejps.2019.04.003","article-title":"The mechanisms of pharmacokinetic food-drug interactions - a perspective from the UNGAP group","volume":"134","author":"Koziolek","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"643","DOI":"10.3390\/pharmaceutics14030643","article-title":"Pharmacokinetic variability in pre-clinical studies: sample study with abiraterone in rats and implications for short-term comparative pharmacokinetic study designs","volume":"14","author":"Kralovicova","year":"2022","journal-title":"Pharmaceutics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.2147\/DDDT.S356967","article-title":"Reduced the food effect and enhanced the oral bioavailability of ivacaftor by self-nanoemulsifying drug delivery system (SNEDDS) using a new oil phase","volume":"16","author":"Miao","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/01.mjt.0000212703.71625.26","article-title":"The pharmacokinetics of cinacalcet are unaffected following consumption of high- and low-fat meals","volume":"14","author":"Padhi","year":"2007","journal-title":"Am. J. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/17476348.2020.1682998","article-title":"Tezacaftor and ivacaftor for the treatment of cystic fibrosis","volume":"14","author":"Paterson","year":"2020","journal-title":"Expert Rev. Resp. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrd2197","article-title":"Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs","volume":"6","author":"Porter","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"B23","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1111\/bph.15644","article-title":"Validity of cycloheximide chylomicron flow blocking method for the evaluation of lymphatic transport of drugs","volume":"178","author":"Rysanek","year":"2021","journal-title":"Brit J. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s11095-020-02858-0","article-title":"Lymphatic transport of drugs after intestinal absorption: impact of drug formulation and physicochemical properties","volume":"37","author":"Rysanek","year":"2020","journal-title":"Pharm. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"122627","DOI":"10.1016\/j.ijpharm.2023.122627","article-title":"Serum and lymph pharmacokinetics of nilotinib delivered by yeast glucan particles per os","volume":"634","author":"Salamunova","year":"2023","journal-title":"Int. J. Pharm."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/jcph.741","article-title":"Effect of low- and high-fat meals on the pharmacokinetics of venetoclax, a selective first-in-class BCL-2 inhibitor","volume":"56","author":"Salem","year":"2016","journal-title":"J. Clin. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"52389","DOI":"10.3791\/52389","article-title":"The mesenteric lymph duct cannulated rat model: application to the assessment of intestinal lymphatic drug transport","volume":"97","author":"Trevaskis","year":"2015","journal-title":"J. Vis. Exp."},{"key":"B28","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00228-007-0276-6","article-title":"Does coronary artery bypass surgery affect metoprolol bioavailability","volume":"63","author":"Valtola","year":"2007","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/0006-2952(62)90078-3","article-title":"Studies on the digestion, absorption and metabolism of castor oil","volume":"11","author":"Watson","year":"1962","journal-title":"Biochem. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Meth Prog. Bio"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1331637\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T05:44:00Z","timestamp":1708407840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1331637\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":30,"alternative-id":["10.3389\/fphar.2024.1331637"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1331637","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"article-number":"1331637"}}